newsfilter
← Latest News
GlobeNewswire·

Cara Therapeutics Reports First Quarter 2023 Financial Results

– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by